A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
In patients with recurrent or metastatic renal cell carcinoma, a preliminary evaluation of
the safety and efficacy of sintilimab combined with axitinib in patients with advanced renal
cell carcinoma was conducted.Progression-free survival (PFS), overall survival (OS), disease
control rate (DCR) and disease remission rate (ORR) were evaluated.